|
|
Volumn 104, Issue 12, 2012, Pages 891-892
|
|
Drug shortages delay cancer clinical trials.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADENINE NUCLEOTIDE;
ANTINEOPLASTIC AGENT;
ARABINONUCLEOSIDE;
CLOFARABINE;
CYTARABINE;
DAUNORUBICIN;
GENERIC DRUG;
ACUTE GRANULOCYTIC LEUKEMIA;
AGED;
CHILD;
CLINICAL TRIAL (TOPIC);
DRUG APPROVAL;
DRUG INDUSTRY;
EUROPE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
METHODOLOGY;
MORTALITY;
NATIONAL HEALTH ORGANIZATION;
NOTE;
PATIENT SELECTION;
STANDARD;
SURVIVAL;
TIME;
UNITED STATES;
ADENINE NUCLEOTIDES;
AGED;
ANTINEOPLASTIC AGENTS;
ARABINONUCLEOSIDES;
CHILD;
CLINICAL TRIALS AS TOPIC;
CYTARABINE;
DAUNORUBICIN;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUGS, GENERIC;
EUROPE;
HUMANS;
LEUKEMIA, MYELOID, ACUTE;
NATIONAL CANCER INSTITUTE (U.S.);
PATIENT SELECTION;
SURVIVAL ANALYSIS;
TIME FACTORS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84865190395
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djs293 Document Type: Note |
|
Times cited : (12)
|
|
References (0)
|
